/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

C4 Therapeutics, Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$2.77 0.1564(15.64%) CCCC at 04 Dec 2025 04:28 PM Biotechnology
Lowest Today 2.42
Highest Today 2.84
Today’s Open 2.45
Prev. Close 2.43
52 Week High 5.10
52 Week Low 1.09
Day’s Range: Low 2.42 High 2.84
52-Week Range: Low 1.09 High 5.10
1 day return -
1 Week return +3.69
1 month return +24.61
3 month return +4.65
6 month return +84.26
1 year return -28.31
3 year return -66.26
5 year return -91.72
10 year return -

Institutional Holdings

Wasatch Advisors LP 10.43

Soleus Capital Management, L.P. 9.81

Orbimed Advisors, LLC 9.60

Wasatch Ultra Growth 7.24

Morgan Stanley - Brokerage Accounts 6.68

Vanguard Group Inc 4.24

Vanguard Total Stock Mkt Idx Inv 2.85

Bank of America Corp 2.82

BlackRock Inc 2.57

Biotech Growth Ord 2.46

Bain Capital Life Sciences Investors, LLC 1.56

Millennium Management LLC 1.55

Renaissance Technologies Corp 1.54

TANG CAPITAL MANAGEMENT LLC 1.26

Goldman Sachs Group Inc 1.24

Two Sigma Advisers, LLC 1.14

Geode Capital Management, LLC 1.05

Two Sigma Investments LLC 0.96

Vanguard Institutional Extnd Mkt Idx Tr 0.86

UBS Group AG 0.80

Jane Street Group LLC 0.69

Jacobs Levy Equity Management, Inc. 0.62

Dimensional Fund Advisors, Inc. 0.61

AQR Capital Management LLC 0.54

Wasatch Long/Short Alpha Institutional 0.50

iShares Biotechnology ETF 0.46

Fidelity Extended Market Index 0.44

Wasatch Long Short Alpha Composite 0.42

Renaissance Global Small Cap 0.38

Schwab US Small-Cap ETF™ 0.37

Invesco RAFI US 1500 Small-Mid ETF 0.21

iShares Micro-Cap ETF 0.19

Fidelity Enhanced Small Cap ETF 0.19

Wasatch Global Small Cap Composite 0.17

Dimensional US Targeted Value ETF 0.17

Extended Equity Market Fund K 0.17

Wasatch Global Opportunities Investor 0.17

Dimensional US Small Cap ETF 0.16

Fidelity Total Market Index 0.15

Bridgeway Ultra-Small Company Market 0.14

Market Status

Strong Buy: 4

Buy: 0

Hold: 4

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 235.50 M

PB Ratio 1.7009

PE Ratio 0.0

Enterprise Value 132.22 M

Total Assets 349.60 M

Volume 4013627

Company Financials

Annual Revenue FY23:20349000 20.3M, FY22:31096000 31.1M, FY21:45785000 45.8M, FY20:33195000 33.2M, FY19:21381000 21.4M

Annual Profit FY23:null 0.0M, FY22:31096000 31.1M, FY21:45785000 45.8M, FY20:33195000 33.2M, FY19:21381000 21.4M

Annual Net worth FY23:-134924000 -134.9M, FY22:-126499000 -126.5M, FY21:-86037000 -86.0M, FY20:-66335000 -66.3M, FY19:-34099000 -34.1M

Quarterly Revenue Q3/2025:11230000 11.2M, Q2/2025:6463000 6.5M, Q1/2025:7238000 7.2M, Q3/2024:15362000 15.4M, Q2/2024:12006000 12.0M

Quarterly Profit Q3/2025:11230000 11.2M, Q2/2025:6463000 6.5M, Q1/2025:7238000 7.2M, Q3/2024:13306000 13.3M, Q2/2024:9961000 10.0M

Quarterly Net worth Q3/2025:-32166000 -32.2M, Q2/2025:-26020000 -26.0M, Q1/2025:-26322000 -26.3M, Q3/2024:-24666000 -24.7M, Q2/2024:-17716000 -17.7M

Fund house & investment objective

Company Information C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Organisation Biotechnology

Employees 110

Industry Biotechnology

CEO Mr. Andrew J. Hirsch M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow